Xeris Biopharma Exceeds Full-Year 2025 Revenue Guidance with Strong Preliminary Results
XERS has more than doubled off its 52-week low of $3.14 on elevated volume (1.9× avg).
Summary
Xeris Biopharma reported preliminary full-year 2025 revenue of $292 million, exceeding its guidance and reflecting 44% year-over-year growth, alongside positive Adjusted EBITDA and strengthened IP.
Key Events · Earnings and Guidance · XERS
-
Exceeds Full-Year Revenue Guidance
Reported preliminary total revenue of $292 million for full-year 2025, surpassing the guidance range of $285-$290 million.
-
Strong Year-Over-Year Growth
Full-year 2025 revenue reflects a 44% increase compared to the prior year, driven by strong product performance.
-
Key Product Performance
Recorlev® net revenue reached $139 million for the full year, with approximately 700 patients on therapy. Gvoke® revenue grew over 13%, and Keveyis® saw a growing patient base.
-
Positive Adjusted EBITDA
The company achieved positive Adjusted EBITDA in every quarter of 2025.
Analysis · XERS · Life Sciences
Xeris Biopharma Holdings, Inc. announced preliminary financial results for the fourth quarter and full year 2025, reporting total revenue of $292 million, which surpassed its previous guidance range of $285-$290 million. This performance represents a significant 44% year-over-year growth, driven by strong contributions from its key products, Recorlev®, Gvoke®, and Keveyis®. The company also achieved positive Adjusted EBITDA in every quarter and strengthened its intellectual property portfolio, indicating robust operational execution and a positive outlook for sustained growth.
At the time of this filing, XERS was trading at $7.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $3.14 to $10.08. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.